J&J takes on Tagrisso in lung cancer, builds bladder cancer foundation

An oncology strategy rooted in combining mechanisms to push efficacy ever higher is highlighted in the data Johnson & Johnson is presenting at the ESMO 2023 Congress. A trio of Phase III lung cancer trials designed to shed more light on how its bispecific antibody Rybrevant — alone or in combination — stacks up against standard of care is drawing the most interest. 

On Monday, Johnson & Johnson (NYSE:JNJ) will present highly anticipated data from the first of the three trials, the MARIPOSA study of EGFR x MET bispecific antibody Rybrevant amivantamab in first-line non-small cell lung cancer (NSCLC) harboring any of the common EGFR mutations. ...